(Reuters) -Drugmaker Bristol Myers Squibb and private equity firm Bain Capital will launch an independent company focused on ...

Bristol Myers will get a nearly 20% stake in the startup, which will be led by one of its former executives, Dan Lynch, and ...

The company will begin with five potential treatments for autoimmune diseases in-licensed from Bristol Myers Squibb, which ...

Bristol Myers Squibb and Bain Capital launch a new biopharma firm focused on autoimmune disease treatments, starting with 5 ...

We recently compiled a list of 11 Best Undervalued Stocks to Invest in Now. Lincoln National Corporation stands third on our ...

US pharma major Bristol Myers Squibb and Bain Capital announced the creation of a new independent biopharmaceutical company ...

London-based buyout firm CapVest Partners is in talks to acquire a majority stake in German drugmaker Stada Arzneimittel, ...

The biopharma spinoff will advance the development of its five investigational therapies designed to treat autoimmune disease.

BMS is spinning out a new company with five immunology assets, including oral drugs being developed for systemic lupus ...

Bristol Myers Squibb is spinning off a fresh company armed with five autoimmune disease drugs and $300 million in Bain ...

Princeton: Bristol Myers Squibb and Bain Capital have announced the formation of a new independent biopharmaceutical company, ...

Bain Capital’s exit leaves Perpetual negotiating with Oaktree-backed financial planner roll-up AZ Next Generation Advisory.